ArticleRespiratory research2020
Pentraxin 3 promotes airway inflammation in experimental asthma.
Article in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Serum pentraxin-3 in patients with chronic obstructive pulmonary disease: A meta-analysis.Biomolecules & biomedicine · 2024Pooled it
- Investigating the Therapeutic Potential of Agarwood Nanoemulsion in Modulating TGF-β-Induced Airway Remodelling in BEAS-2B Cells.Cell biochemistry and biophysics · 2026Article
- 1,25-Dihydroxyvitamin D3 ameliorates neutrophilic asthma through modulation of ERS-NLRP3 inflammasome axis in a mouse model.Iranian journal of basic medical sciences · 2026Article
- Pentraxin 3 deficiency exacerbates neutrophilic inflammation and airway hyperresponsiveness in type 2-low asthma.Frontiers in allergy · 2026Article
- Development and validation of a machine learning-based diagnostic model for identifying nonneutropenic invasive pulmonary aspergillosis in suspected patients: a multicenter cohort study.Microbiology spectrum · 2025Article
- Bullous pemphigoid induced by anti-IL-23 monoclonal antibody in a psoriatic patient: a case report.Frontiers in medicine · 2025Article
- Pentraxin-3 modulates hepatocyte ferroptosis and the innate immune response in LPS-induced liver injury.Molecular biomedicine · 2024Article
- Article
- ST2-Mediated Neutrophilic Airway Inflammation: A Therapeutic Target for Patients With Uncontrolled Asthma.Allergy, asthma & immunology research · 2024Article
- RNA mNature communications · 2023Article
- PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications.Cardiovascular research · 2023Article
- Clinical Utility of Circulating Pentraxin 3 as a Prognostic Biomarker in Coronavirus Disease 2019: A Systematic Review and Meta-analysis.Infectious diseases and therapy · 2023Review
- Blockade of the pentraxin 3/CD44 interaction attenuates lung injury-induced fibrosis.Clinical and translational medicine · 2022Article
- Identification of Key Signaling Pathways and Genes in Eosinophilic Asthma and Neutrophilic Asthma by Weighted Gene Co-Expression Network Analysis.Frontiers in molecular biosciences · 2022Article
- TGF-β1 Signaling: Immune Dynamics of Chronic Kidney Diseases.Frontiers in medicine · 2021Review
- Identification of Genetic Signature Associated With Aging in Pulmonary Fibrosis.Frontiers in medicine · 2021Article
- The Potential Effects of Curcumin on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)-Approaching with Next-Generation Sequencing and Bioinformatics.Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPentraxin 3 (PTX3) regulates multiple aspects of innate immunity and tissue inflammation. Recently, it has been reported that PTX3 deficiency enhances interleukin (IL)-17A-dominant pulmonary inflammation in an ovalbumin (OVA)-induced mouse asthma model. However, whether PTX3 treatment would provide protection against allergic airway inflammation has not been clearly elucidated. The goal of this study was to further investigate the effect of recombinant PTX3 administration on the phenotype of asthma.
methodsC57BL/6 J mice were sensitized and challenged with OVA to induce eosinophilic asthma model, as well as sensitized with OVA plus LPS and challenged with OVA to induce neutrophilic asthma model. We evaluated effect of recombinant PTX3 on asthma phenotype through both asthma models. The bronchoalveolar lavage fluid (BALF) inflammatory cells and cytokines, airway hyperresponsiveness, and pathological alterations of the lung tissues were assessed.
resultsIn both eosinophilic and neutrophilic asthma models, PTX3 treatment provoked airway hyperresponsiveness, concomitant with increased inflammatory cytokines IL-4, IL-17, eotaxin, and transforming growth factor (TGF)-β1 and aggravated airway accumulation of inflammatory cells, especially eosinophils and neutrophils. In histological analysis of the lung tissue, administration of PTX3 promoted inflammatory cells infiltration, mucus production, and collagen deposition. In addition, PTX3 also significantly enhanced STAT3 phosphorylation in lung tissue.
conclusionOur results show that exogenous PTX3 can exacerbate multiple asthmatic features by promoting both eosinophils and neutrophils lung infiltration and provide new evidence to better understand the complex role of PTX3 in allergic airway inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.